Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phenotypic and Prognostic Correlates of Spliceosome Mutations ( SRSF2 , SF3B1 , U2AF35 ) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.

Mrinal M. Patnaik, MBBS, MD, Terra L Lasho, MT, (ASCP), Curtis A Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 2803.

https://doi.org/10.1182/blood.V120.21.2803.2803

Published: 2012

Journal Articles

Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Saad J. Sirop, MD, Aref Al-Kali, MD, Kebede Begna, MD, Naseema Gangat, MD, Louis Letendre, MD, Luis F. Porrata, MD, William J Hogan, MD, Mark R Litzow, MD, Mrinal M. Patnaik, MBBS, MD

Blood (2012) 120 (21): 1476.

https://doi.org/10.1182/blood.V120.21.1476.1476

Published: 2012

Journal Articles

Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients

Mrinal M. Patnaik, MBBS, MD, Curtis A Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 3790.

https://doi.org/10.1182/blood.V120.21.3790.3790

Published: 2012

Journal Articles

Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)

Naseema Gangat, MD, Mrinal M. Patnaik, MBBS, MD, Kebede Begna, MD, Taxiarchis Kourelius, MD, Ryan A Knudson, Rhett P Ketterling, MD, Janice M Hodnefield, MS, MT(ASCP), Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 423.

https://doi.org/10.1182/blood.V120.21.423.423

Published: 2012

Journal Articles

Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)

Kirupananthan Seenithamby, Angela Dispenzieri, MD, Martha Q Lacy, MD, Shaji K. Kumar, MD, Francis K Buadi, M.D., Suzanne R Hayman, MD, David Dingli, M.D., Ph.D., Mark R Litzow, MD, Dennis A. Gastineau, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Stephen M. Ansell, M.D., Ph.D., Patrick B. Johnston, MD, PhD, Luis F. Porrata, MD, Mrinal M. Patnaik, MBBS, MD, William J Hogan, MBBCh, Morie Abraham A Gertz, MD

Blood (2012) 120 (21): 600.

https://doi.org/10.1182/blood.V120.21.600.600

Published: 2012

Journal Articles

Spliceosome Mutations Involving SRSF2 , SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis

Mrinal M. Patnaik, MBBS, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Curtis A Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 1711.

https://doi.org/10.1182/blood.V120.21.1711.1711

Published: 2012

Journal Articles

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Veena Devi Salem Fauble, MD, James L Slack, MD, William Hogan, MD, Vivek Roy, M.D., Jose Leis, MD, PhD, Amylou C. Dueck, PhD, Mark R Litzow, MD, Mrinal M. Patnaik, MBBS, MD, Pardanani Animesh, MBBS, PhD, Candido E. Rivera, MD, Raoul Tibes, MD, PhD, John Camoriano, MD, Roberta H. Adams, MD, Pierre Noel, MD, Nandita Khera, MD, Lisa Sproat, MD, MSW, Ruben A. Mesa

Blood (2012) 120 (21): 2850.

https://doi.org/10.1182/blood.V120.21.2850.2850

Published: 2012

Journal Articles

SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value

Mrinal M. Patnaik, MBBS, MD, Terra L Lasho, MT, (ASCP), Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Aref Al-Kali, MD, Guillermo Garcia-Manero, David P. Steensma, MD, Animesh Pardanani, MBBS, PhD, Curtis A Hanson, Ayalew Tefferi, MD

Blood (2011) 118 (21): 460.

https://doi.org/10.1182/blood.V118.21.460.460

Published: 2011

Journal Articles

Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients

Mrinal M. Patnaik, MBBS, MD, Curtis A. Hanson, MD, Janice M Hodnefield, MS, MT(ASCP), Terra L Lasho, MT, (ASCP), Christy Finke, BS, Ryan A Knudson, Rhett P Ketterling, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 971.

https://doi.org/10.1182/blood.V118.21.971.971

Published: 2011

Journal Articles

Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,

Mrinal M. Patnaik, MBBS, MD, Curtis A Hanson, Nanna Sulai, Janice M Hodnefield, MS, MT(ASCP), Ryan A Knudson, Rhett P Ketterling, MD, Terra L Lasho, MT, (ASCP), Ayalew Tefferi, MD

Blood (2011) 118 (21): 3803.

https://doi.org/10.1182/blood.V118.21.3803.3803

Published: 2011

Journal Articles

No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer

Aaron S. Mansfield, MD, Mark A Lewis, MD, Mrinal M. Patnaik, MBBS, MD, Noralane M Lindor, MD, Matthew P Goetz, MD, Mark R. Litzow, MD

Blood (2011) 118 (21): 4259.

https://doi.org/10.1182/blood.V118.21.4259.4259

Published: 2011

Journal Articles

Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Sania Raza, MD, Mrinal M. Patnaik, MBBS, MD, Andrew L Feldman, MD, Stephen M. Ansell, MD, PhD

Blood (2010) 116 (21): 2705.

https://doi.org/10.1182/blood.V116.21.2705.2705

Published: 2010

Journal Articles

Clinical & Molecular Analysis of Patients with Type 2 (Qualitative) Hereditary Antithrombin (AT) Deficiency

Mrinal M. Patnaik, MBBS, MD, Jennifer Guenther, Rajiv Pruthi, MBBS, John Heit, MD

Blood (2010) 116 (21): 4201.

https://doi.org/10.1182/blood.V116.21.4201.4201

Published: 2010

Journal Articles

Monosomal Karyotype In Myelodysplastic Syndromes, with or without Monosomy 7 or 5, Is Prognostically Worse Than An Otherwise Complex Karyotype

Mrinal M. Patnaik, MBBS, MD, Curtis A. Hanson, MD, Janice Hodnefield, MS, MT(ASCP), Ryan Knudson, Van Dyke L Daniel, Ph.D, Ayalew Tefferi, MD

Blood (2010) 116 (21): 2918.

https://doi.org/10.1182/blood.V116.21.2918.2918

Published: 2010

NARROW

Phenotypic and Prognostic Correlates of Spliceosome Mutations ( SRSF2 , SF3B1 , U2AF35 ) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts.

Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients

Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)

Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)

Spliceosome Mutations Involving SRSF2 , SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value

Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients

Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,

No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer

Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Clinical & Molecular Analysis of Patients with Type 2 (Qualitative) Hereditary Antithrombin (AT) Deficiency

Monosomal Karyotype In Myelodysplastic Syndromes, with or without Monosomy 7 or 5, Is Prognostically Worse Than An Otherwise Complex Karyotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only